« Return to News | Drug Sponsors

OPKO Health acquires Farmadiet Group Holding

Friday, August 3, 2012 10:38 AM

OPKO Health, a global biopharmaceutical and diagnostics company, has decided to acquire Farmadiet Group Holding, a Spanish company that develops, manufactures and markets pharmaceutical, nutraceutical and veterinary products.

With this acquisition, OPKO establishes a presence in the E.U. through an established regional, integrated specialty pharmaceutical participant. The acquisition also allows OPKO near term product commercialization synergies through introduction of Farmadiet’s products to OPKO’s existing Latin American operations. Farmadiet’s product development pipeline also offers many near-term new product entry opportunities.

"This acquisition is an excellent strategic fit as we expand our global manufacturing, sales and distribution capabilities for a growing range of products,” said Phillip Frost, M.D., chairman and CEO of OPKO. “We anticipate important launches near-term of products from Farmadiet’s rich pipeline. We also expect Farmadiet to market OPKO’s diagnostics and pharmaceutical products as they become available for market and sale.”

Further details of the agreement will be included in OPKO’s 8-K filing with the Securities and Exchange Commission.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.